Apollo Cancer Centres Launch ‘End-O Check’ to Tackle Silent Threat of Endometrial and Ovarian Cancers
Bengaluru, NFAPost: Strengthening its leadership in women-centric oncology care, Apollo Cancer Centres (ACCs) has unveiled ‘End-O Check’, a comprehensive early screening and diagnostic program aimed at identifying endometrial and ovarian cancers—two of the most prevalent yet underdiagnosed cancers in women. The program targets women aged 45 and above, especially those in the postmenopausal demographic, offering a much-needed tool in India’s fight against rising gynecological cancer rates.
Often termed the “silent killer,” ovarian cancer typically manifests with vague symptoms and is commonly diagnosed late, leading to poor outcomes. The average age of diagnosis is 63, but when detected early, the five-year survival rate jumps above 90%. Meanwhile, endometrial cancer, although more symptomatic in early stages, often goes unreported due to lack of awareness, leading to delayed diagnoses and diminished treatment outcomes.
India is facing a sharp increase in cancer cases, projected to reach 1.57 million by 2025, with uterine and ovarian cancers consistently ranking among the top five malignancies affecting Indian women. The age-standardized incidence ratesstand at 4.6 per 100,000 for ovarian cancer and 2.5 per 100,000 for endometrial (corpus uterine) cancer. The surge is driven by shifting reproductive trends, urban lifestyles, delayed childbearing, obesity, diabetes, and hormonal imbalances—factors that necessitate targeted, risk-based screening models like End-O Check.
“Early detection remains our most powerful ally in improving survival and quality of life in cancer care,” said Dinesh Madhavan, President, Group Oncology & International, Apollo Hospitals Enterprise Ltd. “End-O Check is a proactive step towards shifting the narrative from reactive treatment to timely screening and personalized care by multidisciplinary cancer management teams.”
The program offers risk-based evaluations, symptom assessments, and diagnostic testing including Transvaginal Sonography (TVS), a non-invasive imaging technique that can detect subtle abnormalities in the ovaries and uterus at an early stage.
Dr. Rani Bhat, Senior Consultant – Gynae Oncology at Apollo Cancer Centre, Bengaluru, emphasized, “Endometrial cancer has seen a noticeable rise in India. Survival rates for localized disease reach 96%, but these drop sharply with delayed diagnosis. That’s why timely identification of risk factors such as PCOS, obesity, diabetes, early menstruation, and late menopause is so critical.”
Dr. Aruna R Patil, Senior Consultant and Head of Radiology at Apollo Cancer Centre, Bengaluru, noted, “Radiology is pivotal in early detection. Through End-O Check, we are using high-resolution transvaginal ultrasounds to pick up early signs, empowering clinicians to act swiftly and decisively.”
End-O Check underscores Apollo’s commitment to preventive oncology by empowering women through education, proactive screening, and early intervention. The initiative is expected to play a significant role in bridging the early diagnosis gap, particularly in a country where awareness and access to gynecologic screening remain limited in many regions.
Whether it’s unexpected bleeding, persistent bloating, pelvic discomfort, or just a family history of gynecologic cancers, End-O Check encourages women to listen to their bodies and seek timely medical evaluation.
With this initiative, Apollo Cancer Centres once again demonstrates its resolve to help women #WinOverCancer — not just through advanced treatment but through awareness, access, and action.
